Safety and Efficacy of Faricimab in Patients With NPDR

Summary

The purpose of this Phase 2 study is comprised of two groups to evaluate the safety, tolerability, and efficacy of faricimab in patients with Non-Proliferative Diabetic Retinopathy.

Timeline

Start

2023-05-16

Primary completion

2026-02-26

Completion

2026-02-26

Publications

• Zhou AW, Sahraravand RA, Baumann LM, Teagle GM, Brown J, Pieramici D, Holy SE, Borne MJ, Wong RW, Cunningham MA, Pearce WA, Rahman EZ, Chang M, Bhavsar AR, Brown DM, Alfaro DV, Fan KC, Cehofski LJ, Ip M, Sadda SR, Lesmes LA, Ehlers JP, Chaudhary V, Al-Khersan H, Wykoff CC. MAGIC: Study Design and Rationale for the Phase 2 Clinical Trial of Faricimab for Non-Proliferative Diabetic Retinopathy. Ophthalmologica. 2026;249(3):265-274. doi: 10.1159/000550491. Epub 2026 Jan 26.

Drugs

Indications